Clinical Trial Update: Efficacy and Safety of LCZ696A in Patients With Essential Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the efficacy and safety of LCZ696A (sacubitril/valsartan) for essential hypertension, reporting effects on blood pressure and tolerabi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• LCZ696A (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2015-08-10